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IL-12 is a heterodimeric, pro-inflammatory cytokine that
enhances the cytotoxic activity of natural killer (NK) cells
and cytotoxic CD8+ T-lymphocytes, and induces an IFN-
a-dominated Th1 CD4+ T-lymphocyte response. IL-12 as
an immunotherapeutic agent administered subcutaneously
in cancer patients has demonstrated clinical responses in
melanoma, T cell lymphoma, non-Hodgkin’s lymphoma,
and AIDS-related Kaposi sarcoma, but was never devel-
oped further. Having elucidated novel hematological prop-
erties of IL-12, we are advancing our proprietary
recombinant human IL-12 (NM-IL-12) for the treatment
of the Hematopoietic Syndrome of Acute Radiation
Syndrome. In three clinical safety studies conducted in
over 200 healthy human volunteers, subcutaneous NM-IL-
12 was well-tolerated. No adverse immune reactions or
immunogenicity were observed.
We have now developed a novel clinical paradigm for
the use of subcutaneously administered, low dose NM-
IL-12 combined with standard of care radiotherapy,
chemotherapy, or immunotherapy for the treatment of
cancer. The pleiotropic effects of IL-12 are expected to
augment the mechanistic, anti-tumor effects of each of
these treatments.
In vitro NM-IL-12 stimulated primary human NK cell
secretion of IFN-g and the cytotoxic lysis of leukemic
cells, and inhibited production of pro-angiogenic IL-17 in
human peripheral blood mononuclear cells. In vivo,
recombinant murine IL-12 (rMuIL-12) caused significant
tumor growth inhibition following total body irradiation
(625cGy) in syngeneic Lewis lung and EL4 lymphoma
tumor models. In the same models, rMuIL-12 in combina-
tion with cyclophosphamide also caused significant tumor
growth inhibition. In the case of the non-immunogenic
Lewis lung cancer model the combination of chemother-
apy and IL-12 enhanced immunogenicity. In both tumor
models, the antitumor effects of IL-12 were accompanied
by rapid recovery of neutrophils, platelets and red blood
cells, depressed by radiation or chemotherapy. This sug-
gests an additional benefit of NM-IL-12 to cancer patients
myelosuppressed following radiation or chemotherapy.
Preclinical evaluation of NM-IL-12 with radiation
therapy and chemotherapy is now followed by evaluating
combination immunotherapy. PD-1 blockade elicits
potent anti-tumor immunity in a subset of melanoma
patients. We have thus evaluated the combination of
rMuIL-12 and anti-PD-1 antibody in a clinically rele-
vant, syngeneic model of spontaneous, highly metastatic
B16 mouse melanoma has been tested.
In summary we show that NM-IL-12 has excellent
anti-tumor potential when used preclinically in combi-
nation with standard of care anti-cancer treatments,
including radiation, chemotherapy and immunotherapy.
NM-IL-12 is expected to contribute durable anti-tumor
responses in the clinic through potent immunoactivation
and anti-angiogenic effects, and to replenish blood cells,
while being safe, well tolerated and non-immunogenic.
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